查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1631213

生技藥品契約製造市場規模、佔有率、趨勢分析報告：按產品、適應症、地區、細分市場預測，2025-2030 年

Biologics Contract Manufacturing Market Size, Share & Trends Analysis Report By Product (MABs, Recombinant Protein), By Indication (Oncology, CVDs), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10個工作天內

價格

生技藥品契約製造市場的成長與趨勢

根據 Grand View Research, Inc. 的一份新報告，全球生技藥品契約製造市場規模預計將到 2030 年達到 575.9 億美元，2025 年至 2030 年期間的複合年成長率為 10.3%。全球市場在新冠疫情期間高效率成長。這是由於活性化了對 COVID-19 疫苗的研發活動。此外，還擴大了生產設施，以遏制感染的蔓延。例如，2021年11月，龍沙宣布決定擴建其位於瑞士的微生物學開發實驗室，以支持公司即將進行的計劃。

預計疫情過後將發生許多根本性變化。我們將看到針對冠狀病毒的疫苗和治療方法的生產和製造力度加大，所有業務部門的數位化能力也將增強。這些努力將有助於與製藥公司製定共同規劃，建立更具策略性的夥伴關係。例如，2022 年 1 月，Lonza 宣布了一項用於發現和設計特異性抗體的技術，稱為 bYlok(TM)。全球製藥和生技藥品製造的外包正在迅速成長。

製藥和生物技術公司正在降低與生產藥品和生技藥品相關的營運成本，同時專注於其核心計劃。受託製造廠商(CMO) 具有執行整個製造過程的專業知識和經驗。生技藥品的內部製造具有挑戰性，因為它是一個複雜且資源密集的過程。透過專注於改善藥物發現過程，CMO 可以彌合需求和供應之間的差距，從而更快地將生技藥品送到患者手中。因此，外包正在迅速成長。

生技藥品契約製造市場報告重點

  • 根據產品，MAB 部門預計將在 2024 年佔據最大的收入佔有率，因為 MAB 用於治療多種疾病，包括癌症、感染疾病、氣喘和自體免疫疾病。
  • 根據適應症，腫瘤學在 2024 年佔據市場主導地位，收益佔有率最大。該部分佔有率較高的主要因素是癌症患者數量的增加。
  • 由於製藥和生技藥品製造外包服務的增加以及高昂的研發成本，北美在 2024 年佔據了全球市場的主導地位。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第 3 章生物製藥契約製造市場變數、趨勢與範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析 – 波特五力分析
    • PESTLE分析

第 4 章生物製藥契約製造市場：產品業務分析

  • 2024 年及 2030 年產品市場佔有率
  • 產品細分儀表板
  • 2018 年至 2030 年按產品分類的市場規模、預測與趨勢分析
  • 單株抗體（mAb）
  • 重組蛋白
  • 疫苗
  • 反義、RNAi 和分子治療
  • 其他

第5章生物製藥契約製造市場：適應症業務分析

  • 2024 年和 2030 年指示市場佔有率
  • 指示細分儀表板
  • 2018 年至 2030 年按適應症分類的市場規模、預測與趨勢分析
  • 腫瘤學
  • 自體免疫疾病
  • 感染疾病
  • 心血管疾病
  • 代謝紊亂
  • 神經病學
  • 其他

第6章 生物製藥契約製造市場：按地區、產品和適應症的估計和趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 2018-2030 年市場規模及預測趨勢分析
  • 北美洲
    • 按國家/地區，2018 年至 2030 年
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 按國家/地區，2018 年至 2030 年
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 泰國
    • 韓國
  • 拉丁美洲
    • 按國家/地區，2018 年至 2030 年
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 按國家/地區，2018 年至 2030 年
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭格局

  • 參與者概述
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • Wuxi Biologics.
    • FUJIFILM Diosynth BIoTechnologies.
    • Boehringer Ingelheim International GmbH
    • Lonza
    • Samsung Biologics
    • AbbVie Inc.
    • Catalent
    • Bioreliance（Merck KGaA）
    • Thermo Fisher Scientific Inc.
    • Eurofins Scientific
Product Code: GVR-4-68039-921-6

Biologics Contract Manufacturing Market Growth & Trends:

The global biologics contract manufacturing market size is expected to reach USD 57.59 billion by 2030, registering a CAGR of 10.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. The global market was growing efficiently during the COVID-19 pandemic. This is due to a rise in R&D activities for the development of COVID-19 vaccines. In addition, there has been an expansion in manufacturing facilities to control the spread of the disease. For instance, in November 2021, Lonza announced that it has decided to expand its microbial development laboratories in Switzerland to support the company's upcoming projects.

It is believed that post-pandemic there will be numerous fundamental changes. There will be an increase in the production and manufacturing efforts for the development of vaccines and therapeutics against the coronavirus and a rise in digital capabilities across all their operating units. These initiatives will help them in joint planning with pharma clients in building more strategic partnerships. For instance, in January 2022, Lonza launched a technology that will be used for the discovery and design of antibodies that are biospecific and this technology will be called bYlok(TM). The outsourcing of drugs or biologics manufacturing is rapidly increasing around the world.

Pharmaceutical and biotechnology companies concentrate on their core projects while reducing the operational costs associated with manufacturing drugs or biologics. Contract Manufacturing Organizations (CMOs) are specialized and experienced in conducting the entire process of manufacturing. In-house manufacturing of biologics is difficult as it is a complex process and involves many resources. CMOs link the demand and supply gap by focusing on improving the drug discovery process resulting in faster availability of biologics for patients. Hence, due to these factors, outsourcing activities are rapidly increasing.

Biologics Contract Manufacturing Market Report Highlights:

  • Based on products, the MABs segment accounted for the largest revenue share in 2024 as MABs are used in the treatment of a wide range of diseases, such as cancer, infectious diseases, asthma, and auto-immune diseases
  • Based on indications, the oncology segment dominated the market in 2024 with the largest revenue share. The main factor responsible for the high segment share is the increased number of cancer cases
  • North America dominated the global market in 2024 due to the increased outsourcing services for manufacturing drugs & biologics and high R&D expenditure in the region

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Indication
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Biologics Contract Manufacturing Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Biologics Contract Manufacturing Market: Product Business Analysis

  • 4.1. Product Market Share, 2024 & 2030
  • 4.2. Product Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 4.4. Monoclonal Antibodies (mAbs)
    • 4.4.1. Monoclonal Antibodies (mAbs) Market, 2018 - 2030 (USD Million)
  • 4.5. Recombinant Proteins
    • 4.5.1. Recombinant Proteins Market, 2018 - 2030 (USD Million)
  • 4.6. Vaccines
    • 4.6.1. Vaccines Market, 2018 - 2030 (USD Million)
  • 4.7. Antisense, RNAi, & Molecular Therapy
    • 4.7.1. Antisense, RNAi, & Molecular Therapy Market, 2018 - 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Biologics contract manufacturing Market: Indication Business Analysis

  • 5.1. Indication Market Share, 2024 & 2030
  • 5.2. Indication Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
  • 5.4. Oncology
    • 5.4.1. Oncology Market, 2018 - 2030 (USD Million)
  • 5.5. Autoimmune Diseases
    • 5.5.1. Autoimmune Diseases Market, 2018 - 2030 (USD Million)
  • 5.6. Infectious Diseases
    • 5.6.1. Infectious Diseases Market, 2018 - 2030 (USD Million)
  • 5.7. Cardiovascular Diseases
    • 5.7.1. Cardiovascular Diseases Market, 2018 - 2030 (USD Million)
  • 5.8. Metabolic Diseases
    • 5.8.1. Metabolic Diseases Market, 2018 - 2030 (USD Million)
  • 5.9. Neurology
    • 5.9.1. Neurology Market, 2018 - 2030 (USD Million)
  • 5.10. Others
    • 5.10.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Biologics Contract Manufacturing Market: Regional Estimates & Trend Analysis by Product and Indication

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 6.4. North America
    • 6.4.1. North America Biologics Contract Manufacturing Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Regulatory Framework
      • 6.4.2.3. Competitive Insights
      • 6.4.2.4. U.S. Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Regulatory Framework
      • 6.4.3.3. Competitive Insights
      • 6.4.3.4. Canada Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Regulatory Framework
      • 6.4.4.3. Competitive Insights
      • 6.4.4.4. Mexico Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Biologics Contract Manufacturing Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Regulatory Framework
      • 6.5.2.3. Competitive Insights
      • 6.5.2.4. UK Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Regulatory Framework
      • 6.5.3.3. Competitive Insights
      • 6.5.3.4. Germany Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Regulatory Framework
      • 6.5.4.3. Competitive Insights
      • 6.5.4.4. France Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Regulatory Framework
      • 6.5.5.3. Competitive Insights
      • 6.5.5.4. Italy Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Regulatory Framework
      • 6.5.6.3. Competitive Insights
      • 6.5.6.4. Spain Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Regulatory Framework
      • 6.5.7.3. Competitive Insights
      • 6.5.7.4. Denmark Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Regulatory Framework
      • 6.5.8.3. Competitive Insights
      • 6.5.8.4. Sweden Biologics Contract Manufacturing Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Regulatory Framework
      • 6.5.9.3. Competitive Insights
      • 6.5.9.4. Norway Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Regulatory Framework
      • 6.6.2.3. Competitive Insights
      • 6.6.2.4. Japan Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Regulatory Framework
      • 6.6.3.3. Competitive Insights
      • 6.6.3.4. China Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Regulatory Framework
      • 6.6.4.3. Competitive Insights
      • 6.6.4.4. India Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Regulatory Framework
      • 6.6.5.3. Competitive Insights
      • 6.6.5.4. Australia Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. Thailand
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Regulatory Framework
      • 6.6.6.3. Competitive Insights
      • 6.6.6.4. Thailand Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. South Korea
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Regulatory Framework
      • 6.6.7.3. Competitive Insights
      • 6.6.7.4. South Korea Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Biologics Contract Manufacturing Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Regulatory Framework
      • 6.7.2.3. Competitive Insights
      • 6.7.2.4. Brazil Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Regulatory Framework
      • 6.7.3.3. Competitive Insights
      • 6.7.3.4. Argentina Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8. MEA
    • 6.8.1. MEA Biologics Contract Manufacturing Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Regulatory Framework
      • 6.8.2.3. Competitive Insights
      • 6.8.2.4. South Africa Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Regulatory Framework
      • 6.8.3.3. Competitive Insights
      • 6.8.3.4. Saudi Arabia Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Regulatory Framework
      • 6.8.4.3. Competitive Insights
      • 6.8.4.4. UAE Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Regulatory Framework
      • 6.8.5.3. Competitive Insights
      • 6.8.5.4. Kuwait Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Wuxi Biologics.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. FUJIFILM Diosynth Biotechnologies.
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Boehringer Ingelheim International GmbH
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Lonza
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Samsung Biologics
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. AbbVie Inc.
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Catalent
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Bioreliance (Merck KGaA)
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Thermo Fisher Scientific Inc.
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Eurofins Scientific
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global biologics contract manufacturing market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 5 Global biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 6 North America biologics contract manufacturing market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 8 North America biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 9 U.S. biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 10 U.S. biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 11 Canada biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 12 Canada biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 13 Mexico biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 14 Mexico biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 15 Europe biologics contract manufacturing market, by country, 2018 - 2030 (USD Million)
  • Table 16 Europe biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 17 Europe biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 18 UK biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 19 UK biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 20 Germany biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 21 Germany biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 22 France biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 23 France biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 24 Italy biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 25 Italy biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 26 Spain biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 27 Spain biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 28 Denmark biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 29 Denmark biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 30 Sweden biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 31 Sweden biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 32 Norway biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 33 Norway biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific biologics contract manufacturing market, by country, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 37 Japan biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 38 Japan biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 39 China biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 40 China biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 41 India biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 42 India biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 43 Australia biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 44 Australia biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 45 Thailand biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 46 Thailand biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 47 South Korea biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 48 South Korea biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 49 Latin America biologics contract manufacturing market, by country, 2018 - 2030 (USD Million)
  • Table 50 Latin America biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 51 Latin America biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 52 Brazil biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 53 Brazil biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 54 Argentina biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 55 Argentina biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa Biologics contract manufacturing market, by country, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 59 South Africa biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 60 South Africa biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 62 Saudi Arabia biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 63 UAE biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 64 UAE biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
  • Table 65 Kuwait biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 66 Kuwait biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Biologics contract manufacturing market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Market formulation & validation
  • Fig. 7 Market snapshot
  • Fig. 8 Product and indication outlook (USD Million)
  • Fig. 9 Competitive landscape
  • Fig. 10 Biologics contract manufacturing market dynamics
  • Fig. 11 Biologics contract manufacturing market: Porter's five forces analysis
  • Fig. 12 Biologics contract manufacturing market: PESTLE analysis
  • Fig. 13 Biologics contract manufacturing market: Product segment dashboard
  • Fig. 14 Biologics contract manufacturing market: Product market share analysis, 2024 & 2030
  • Fig. 15 Monoclonal Antibodies (mAbs) market, 2018 - 2030 (USD Million)
  • Fig. 16 Recombinant proteins market, 2018 - 2030 (USD Million)
  • Fig. 17 Vaccines market, 2018 - 2030 (USD Million)
  • Fig. 18 Antisense, RNAi, & molecular therapy market, 2018 - 2030 (USD Million)
  • Fig. 19 Others market, 2018 - 2030 (USD Million)
  • Fig. 20 Biologics contract manufacturing market: Indication segment dashboard
  • Fig. 21 Biologics contract manufacturing market: Indication market share analysis, 2024 & 2030
  • Fig. 22 Oncology market, 2018 - 2030 (USD Million)
  • Fig. 23 Autoimmune diseases market, 2018 - 2030 (USD Million)
  • Fig. 24 Infectious diseases market, 2018 - 2030 (USD Million)
  • Fig. 25 Cardiovascular diseases market, 2018 - 2030 (USD Million)
  • Fig. 26 Metabolic diseases market, 2018 - 2030 (USD Million)
  • Fig. 27 Neurology market, 2018 - 2030 (USD Million)
  • Fig. 28 Others market, 2018 - 2030 (USD Million)
  • Fig. 29 Biologics contract manufacturing market revenue, by region
  • Fig. 30 Regional marketplace: Key takeaways
  • Fig. 31 Regional marketplace: Key takeaways
  • Fig. 32 North America biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 33 U.S. country dynamics
  • Fig. 34 U.S. biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 35 Canada country dynamics
  • Fig. 36 Canada biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 37 Mexico country dynamics
  • Fig. 38 Mexico biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 39 Europe biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 40 UK country dynamics
  • Fig. 41 UK biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 42 Germany country dynamics
  • Fig. 43 Germany biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 44 France country dynamics
  • Fig. 45 France biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 46 Italy country dynamics
  • Fig. 47 Italy biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 48 Spain country dynamics
  • Fig. 49 Spain biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 50 Denmark country dynamics
  • Fig. 51 Denmark biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 52 Sweden country dynamics
  • Fig. 53 Sweden biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 54 Norway country dynamics
  • Fig. 55 Norway biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 56 Asia Pacific biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 57 Japan country dynamics
  • Fig. 58 Japan biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 59 China country dynamics
  • Fig. 60 China biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 61 India country dynamics
  • Fig. 62 India biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 63 Australia country dynamics
  • Fig. 64 Australia biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 65 Thailand country dynamics
  • Fig. 66 Thailand biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 67 South Korea country dynamics
  • Fig. 68 South Korea biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 69 Latin America biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 70 Brazil country dynamics
  • Fig. 71 Brazil biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 72 Argentina country dynamics
  • Fig. 73 Argentina biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 74 MEA biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 75 South Africa country dynamics
  • Fig. 76 South Africa biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 77 Saudi Arabia country dynamics
  • Fig. 78 Saudi Arabia biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 79 UAE country dynamics
  • Fig. 80 UAE biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 81 Kuwait country dynamics
  • Fig. 82 Kuwait biologics contract manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 83 Company categorization
  • Fig. 84 Company market position analysis
  • Fig. 85 Strategic framework